Obviousness

Obviousness Analysis of US Patent 11,021,437 under 35 U.S.C. § 103

This analysis assesses the obviousness of the claims of US patent 11,021,437 ('437 patent) in light of prior art available before its priority date of November 13, 2016. The analysis is based on a combination of prior art references cited in the patent itself.

A claim is considered obvious under 35 U.S.C. § 103 if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA).

Person Having Ordinary Skill in the Art (POSA)

For the purposes of this analysis, a POSA would be a medicinal chemist or pharmaceutical formulation scientist with experience in drug delivery, particularly in developing prodrugs and non-invasive dosage forms. This person would be familiar with the challenges of delivering unstable and poorly absorbed molecules like epinephrine.

---

Analysis of Independent Claims 1 and 4, and Dependent Claims 2, 3, and 5

Claim 1 recites a broad class of epinephrine di-ester prodrugs formulated in a rapidly dissolving film for sublingual or buccal administration, characterized by a specific Log P range (0.5-6.0) and a rapid hydrolysis half-life (1-6 minutes).

Claim 2 recites a narrower class of specific prodrugs from Claim 1, where the ester groups are derived from acetic, propanoic, or isobutyric acid.

Claim 4 recites a specific epinephrine prodrug where R is —C(Cl)₂CH₃, formulated for sublingual or buccal administration.

The primary prior art references for this analysis are:

• US Patent 3,809,714 (Hussain '714): Discloses epinephrine di-ester prodrugs, including those recited in Claim 2, to increase lipophilicity for improved penetration through the cornea for glaucoma treatment.
• US Patent Application Publication 2007/0202163 (Rawas-Qalaji): Discloses fast-disintegrating tablets for sublingual or buccal administration of epinephrine for treating anaphylaxis, highlighting the need for non-injectable alternatives.
• US Patent 4,136,145 (Fuchs): Discloses rapidly dissolving films as a general drug delivery vehicle for mucosal membranes, including the mouth.

Argument for Obviousness:

A combination of Hussain '714, Rawas-Qalaji, and Fuchs would have rendered claims 1, 2, 3, 4, and 5 of the '437 patent obvious to a POSA.

1. Motivation to Pursue Sublingual Epinephrine Prodrugs:
   Rawas-Qalaji establishes the clear and urgent medical need for a non-invasive, fast-acting epinephrine formulation for anaphylaxis as an alternative to auto-injectors. It specifically teaches the sublingual and buccal routes of administration. A 2006 study by the same inventor, cited in the '437 patent's own background section, demonstrated that a very large dose (40 mg) of sublingual epinephrine was required to achieve bioequivalence with a standard 0.3 mg intramuscular injection. A POSA would immediately recognize this as a problem of poor membrane permeability of epinephrine, a known hydrophilic molecule (Log P of -0.68, as stated in the '437 patent).

2. Identification of a Known Solution:
   Faced with the problem of poor sublingual absorption, a POSA would have been motivated to search for known methods to enhance the membrane permeability of epinephrine. The work of Hussain '714 provides a direct and well-documented solution: creating lipophilic di-ester prodrugs. Hussain explicitly teaches the synthesis of 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene di-acetate, dipropionate, and bis(2-methylpropanoate)—the very compounds of claim 2. Although Hussain's stated goal was ocular delivery, a POSA would understand that the underlying principle—increasing lipophilicity via esterification to enhance transport across a biological membrane—is a fundamental concept in medicinal chemistry applicable to any mucosal membrane, including the sublingual or buccal mucosa. Combining Rawas-Qalaji's problem (poor sublingual absorption) with Hussain's known solution (lipophilic prodrugs) would have been obvious.

3. Obviousness of the Dosage Form:
   Rawas-Qalaji teaches a fast-disintegrating tablet. The '437 patent claims a "rapidly dissolving film." Fuchs '145 teaches that medicated films are a known dosage form for administration to mucosal areas, including the mouth. A POSA would have viewed a rapidly dissolving film as a simple and obvious substitute for a fast-disintegrating tablet. Both are established dosage forms designed for rapid drug release in the oral cavity. The choice between them would have been a matter of routine formulation development, not inventive step.

4. Reasonable Expectation of Success and Routine Optimization:
   A POSA would have had a reasonable expectation of success in formulating one of Hussain's prodrugs into a sublingual film. The increased lipophilicity of the prodrugs would be expected to improve absorption compared to epinephrine itself. The claims' limitations regarding Log P and half-life represent parameters that a POSA would routinely optimize.

   • Log P (0.5-6.0): The '437 patent itself notes this range is based on a review of existing marketed sublingual drugs. This confirms it was a known target for formulation scientists. A POSA would calculate or measure the Log P of Hussain's compounds to ensure they fell within this desirable range for sublingual absorption. The '437 patent calculates the Log P for Hussain's compounds (e.g., +0.79 for the compound in Structure 7B), confirming they meet this claim limitation.
   • Half-life (1-6 minutes): For an emergency treatment like anaphylaxis, a rapid conversion of the prodrug to active epinephrine is essential. A POSA would be motivated to select or design a prodrug with a sufficiently fast hydrolysis rate. Hussain's work already involved evaluating hydrolysis rates in plasma. Selecting an ester that hydrolyzes within 1-6 minutes would be a result of routine screening and optimization, not invention.
   • Claim 4 Compound (R = —C(Cl)₂CH₃): While not explicitly disclosed in the cited art, this compound represents a predictable variation of the di-ester theme. Esterification is a common prodrug strategy, and the use of halogenated acyl groups to modulate electronic properties (and thus hydrolysis rates) and lipophilicity is a standard tool in medicinal chemistry. A POSA seeking to fine-tune the hydrolysis rate could have been motivated to introduce electron-withdrawing chlorine atoms near the ester linkage to accelerate the reaction. This would represent "obvious-to-try" routine experimentation for a skilled chemist.

Conclusion:

The core inventive concept of the '437 patent is the use of a known class of epinephrine prodrugs, previously developed for ocular delivery, in a known type of dosage form (a film) for a known clinical need (sublingual delivery for anaphylaxis). The prior art, particularly the combination of Hussain '714, Rawas-Qalaji, and Fuchs, provided a clear motivation and a straightforward path for a POSA to arrive at the claimed invention with a reasonable expectation of success. The specific limitations on Log P and half-life represent functional requirements that would have been addressed through routine optimization rather than an inventive leap.